SBI-0498 (SBI-0730498) is a small molecule inhibitor of coronaviruses translation initiation complex 4F (eIF4F), disrupts eIF4F complex formation and inhibits coronavirus RNA and protein levels.

SBI-5844 (SBI-1275844) is a small molecule inhibitor of coronaviruses translation initiation complex 4F (eIF4F), disrupts eIF4F complex formation and inhibits coronavirus RNA and protein levels.

HPG1860 is a potent, selective, nonbile acid full FXR agonist with EC50 of 5 nM and 18 nM in FR-FRET and luciferase assays, respectively.

ID119031166 (ID166) is a novel potent, selective FXR agonist with EC50 of 3 nM and 5 nM in TR-FRET FXR co-activator assay and FXR reporter assay, respectively.

MET409 (MET-409) is a potent, selective farnesoid X receptor (FXR) agonist with EC50 of 16 nM (human FXR).

PDL103 is a potent, dual FXR/GPBAR1 antagonist with IC50 of 10 and 19 uM, respectively.

3i-1262 is a small molecule GATA4-acting compound that inhibit the GATA4-NKX2-5 interaction, enhances cardiomyocyte identity and maturity.

ER-400583-00 is a small-molecule HIF-1α inhibitor, inhibits the induction of HIF-1 reporter activity in response to hypoxia with IC50 of 7.9 nM.

FG-0041 (FG0041) is a small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase (HIF-PH) with IC50 of 2 uM for collagen prolyl hydroxylase.

MO-2097 is a small molecule hnRNPA2B1-binding compound (ITC KD=43.1 uM) that suppresses hnRNPA2B1-induced HIF-1α protein expression under hypoxic and mimetic hypoxia.

D-F07 is a novel fluorescent, covalent IRE-1 inhibitor, potently inhibits XBP-1s expression in MM cells.

PAIR1 is a partial antagonist of IRE1α RNase (PAIR) that fully engage IRE1α's kinase domain (Ki=220 nM) but only partially inhibit its RNase activity.

TC-D-F07 is a novel prodrug of the covalent IRE-1 inhibitor D-F07, inhibits IRE-1/XBP-1s pathway in cancer cells.

BC-1901S is a potent small molecule NRF2 activator that stabilizes NRF2 and increases NRF2 activity, activates NRF2 by inhibiting NRF2 ubiquitination in a KEAP1-independent manner.

S217879 (S 217879) is a highly potent and selective NRF2 activator, binds to KEAP1 Kelch domain (SPR Kd=4.15 nM), disrupts the KEAP1-NRF2 interaction leading to robust NRF2 pathway activation.

sAKZ692 (sAKZ-692) is a small molecule activator of NRF2 transcriptional activity (EC50=2.2 uM) in cells by inhibiting the glycolytic enzyme pyruvate kinase.

NC114 is a small molecule targeting cancer-associated KLF5 transcription factor, decreases the KLF protein but not mRNA levels of KLF in vitro.

4A7C-301 is a potent, selective, brain-penetrant agonist of nuclear receptor Nurr1 with EC50 of 6.53 uM, binds to Nurr1 ligand binding domain (LBD) with IC50 of 50 nM.

BRF110 is a potent, selective, brain penetrant and vivo active agonist of Nurr1-RXRα heterodimers with EC50 of 900 nM.

SA00025 is a potent, specific and brain penetrant agonist of Nurr1 (NR4A2) with EC50 of 2.5 nM in HEK293 cells transfected with full length human Nurr1.

XCT0135908 (BRF001) is a highly selective activator of Nurr1-RXR heterodimers, stimulates dopamine (DA) neuron survival.

MBX-102 acid is the active form of JNJ39659100 (MBX-102), a selective partial PPAR-γ agonist with EC50 of 23.34 uM (hPPAR-γ), enhances insulin sensitivity in vitro in 3T3-L1 adipocytes, binds to the PPAR-γ LBD in a manner that is distinct from but overla